This is a preview of subscription content, log in via an institution to check access.
Notes
2016 US dollars
Reference
Schnippel K, et al. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Applied Health Economics and Health Policy : 4 Oct 2017. Available from: URL: http://dx.doi.org/10.1007/s40258-017-0352-8
Rights and permissions
About this article
Cite this article
Bedaquiline cost effective for drug-resistant TB. PharmacoEcon Outcomes News 789, 12 (2017). https://doi.org/10.1007/s40274-017-4419-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4419-4